Drug Profile

VPI 2690B

Alternative Names: VPI-2690B

Latest Information Update: 24 Sep 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of North Carolina
Developer Vascular Pharmaceuticals
Class Monoclonal antibodies
Mechanism of Action IGF type 1 receptor antagonists; Integrin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Diabetic nephropathies

Most Recent Events

24 Sep 2020 Phase II development is ongoing for Diabetic nephropathies in Puerto Rico and USA (Vascular Pharmaceuticals website, September 2020)
01 Mar 2017 Vascular Pharmaceuticals completes a phase II trial in Diabetic nephropathies in USA and Puerto Rico (NCT02251067)
09 Dec 2016 VPI 2690B is still in phase II trials for Diabetic nephropathies in USA (NCT02251067)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com